Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 14/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24200731 | 1.00 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21179376 | 0.85 | PSEN1 (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24200607 | 0.82 | PSEN1 (0.61) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2271918 | 0.76 | PSEN1 (0.47) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23443614 | 0.72 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23442943 | 0.72 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21886900 | 0.71 | RIPK1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22494488 | 0.70 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22494460 | 0.70 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22494485 | 0.69 | APP (1.00) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370802-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3743428-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-20210395270-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3743428-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019141832-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141832-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395270-A1 | TRIAZOLO-AZEPINE DERIVATIVES | BACE1, APP, BACE2 | APP 2/4885PSEN1 5/4885PSEN2 8/4885 |
| US-11370802-B2 | Triazolo-azepine derivatives | BACE1, APP, BACE2 | APP 2/4885PSEN1 5/4885PSEN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.